Physician profile
Disha Uttam Shah
NPI 1366671265
$122,083.21
in general payments reported to CMS, 2019-2025
76 companies · $3,929 in 2025
The $3,929 reported for 2025 was more than what 83% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $27K · 2021: $42K · 2022: $19K · 2023: $9,477 · 2024: $2,618 · 2025: $3,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,639 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,750 · Consulting Fee: $2,400 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,638.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,750.00 |
| Consulting Fee | $2,400.00 |
| Education | $234.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $69,171.48 | 2019-2022 | |
| Abbvie INC. | $35,892.29 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Emd Serono, INC. | $2,825.22 | 2020-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,185.24 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Vanda Pharmaceuticals INC. | $1,007.24 | 2025 | Ponvory |
| Ucb, INC. | $758.80 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Livanova USA, INC. | $691.34 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $665.25 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $607.61 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $598.59 | 2019-2025 | |
| Pfizer INC. | $580.23 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $563.08 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $519.91 | 2019-2025 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $433.05 | 2020-2021 | |
| Celgene Corporation | $382.62 | 2022-2025 | Zeposia |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Disha Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.